The key finding
The International Society for Pediatric and Adolescent Diabetes released updated 2024 guidelines that expand treatment recommendations for children and adolescents with diabetes beyond traditional insulin alone. The new guidelines now include guidance on newer-generation insulin formulations—both faster-acting and ultra-long-acting types—as well as adjunctive medications such as GLP-1 receptor agonists, metformin, pramlintide, and SGLT inhibitors that can be used alongside insulin. Critically, the guidelines explicitly address insulin access and affordability as essential components of care, recognizing that cost remains a barrier for many families globally.
What the study looked like
This is not a single research study but rather a comprehensive set of clinical practice guidelines developed by an international panel of pediatric diabetes experts. The guidelines update the 2022 ISPAD recommendations and represent a consensus review of current evidence on managing diabetes in children, adolescents, and young adults. The panel reviewed existing research on intensive insulin regimens, including multiple daily injection protocols, and evaluated evidence for medications traditionally used in adult diabetes but increasingly studied in younger populations. The guidelines are designed to serve healthcare providers worldwide who care for young people with both type 1 and type 2 diabetes, covering age ranges from early childhood through young adulthood.
Why researchers think this happened
The expansion of treatment options reflects several converging developments in pediatric diabetes care. Pharmaceutical advances have produced insulin analogs with pharmacokinetic profiles better suited to mimicking natural insulin secretion—faster-acting formulas that work more quickly after meals and ultra-long-acting versions that provide more stable background coverage. Meanwhile, rising rates of type 2 diabetes in youth and growing evidence that some adjunctive medications (originally approved for adults) may benefit young people have prompted guideline committees to address these options formally. The explicit inclusion of access and affordability discussions stems from persistent global disparities: insulin remains unaffordable or unavailable in many regions, and newer formulations and adjunct treatments often carry even higher price tags, creating potential inequities in care quality.
How to read this carefully
These are expert consensus guidelines, not findings from a controlled trial. While they synthesize available evidence, the quality and quantity of research varies considerably across the recommendations—some newer insulins and adjunctive drugs have limited long-term safety data specifically in pediatric populations. The guidelines must balance aspirational standards (what optimal care could look like with full access to modern treatments) against practical realities in different healthcare settings. Readers should understand that “updated recommendations” does not mean all these options are appropriate for every young person with diabetes, nor that they are accessible everywhere. The emphasis on affordability acknowledges that guideline recommendations mean little if families cannot obtain or afford the recommended treatments. Additionally, some adjunctive medications are used off-label in children, meaning regulatory approval may lag behind emerging clinical practice.
What this means for everyday life
For families managing pediatric diabetes, these guidelines signal that treatment is becoming more nuanced and potentially more flexible. If your child struggles with blood sugar spikes after meals or overnight lows, newer insulin formulations might offer better control—worth discussing with your diabetes care team. The inclusion of adjunctive medications suggests that, in some cases, insulin alone may not be the only option, particularly for youth with type 2 diabetes or specific management challenges. However, the affordability emphasis is equally important: if cost is a barrier, these guidelines support conversations with providers about access programs, insurance coverage, or alternative regimens that work within your financial reality. Given the 2024 publication, these represent current best-practice thinking, though implementation will vary by location and healthcare system. The guidelines essentially validate asking your care team about newer options while acknowledging that access gaps remain a systemic problem requiring advocacy beyond individual clinical encounters.